Company intelligence / Profile preview

The Phene

Ownership: Private
Development stage: Other

Overview

Pheon Therapeutics is advancing a pipeline of next-generation antibody-drug conjugates targeting novel antigens highly expressed in solid tumors. Their lead program has demonstrated an unprecedented preclinical therapeutic index, and the company expects to initiate its first Phase 1 clinical trial in 2024. The pipeline includes three new ADCs with differentiated linker-payload technologies, aiming for improved efficacy and safety over existing therapies

Therapeutic areas: Oncology
Modalities: Antibody-drug conjugateMonoclonal antibody (as component of ADCs)
Industry: Biotech

Beyond the preview

Go deeper on The Phene.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on The Phene.

Explore the full profile